Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Aslan Pharmaceuticals Ltd ADR (ASLN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aslan Pharma ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.512 -0.028    -5.19%
19/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.512
-0.000
-0.000%
23:00:03 - Real-time Data
  • Volume: 25,772
  • Bid/Ask: 0.500 / 0.570
  • Day's Range: 0.501 - 0.570
Type:  Equity
Market:  United States
Aslan Pharma ADR 0.512 -0.028 -5.19%

Aslan Pharma ADR Company Profile

 
Read the Aslan Pharmaceuticals Ltd ADR company profile to learn more about the business and the management team. View Aslan Pharmaceuticals Ltd ADR facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

34

Equity Type

ADR

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy in autoimmune disease. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Contact Information

Address 3 Temasek Avenue Level 18 Centennial Tower
Singapore, 039190
Singapore
Phone 65 6817 9598
Fax -

Top Executives

Name Age Since Title
Carl Alan Jason Morton Firth 50 2010 Founder, CEO & Executive Director
Andrew Howden 64 2016 Independent Chairman
Robert E. Hoffman 57 2018 Independent Non-Executive Director
Lawrence F. Eichenfield 64 2021 Chairman of Scientific Advisory Board
Kathleen M. Metters 66 2021 Independent Director
Eric Simpson - 2021 Member of Scientific Advisory Board
Melinda Jennifer Gooderham - 2021 Member of Scientific Advisory Board
Neil Graham 65 2021 Independent Director
Peter Foley - 2021 Member of Scientific Advisory Board
Reynold A. Panettieri - 2024 Scientific Advisor
Ramaswamy Krishnan - 2024 Scientific Advisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ASLN Price Commentary

Write your thoughts about Aslan Pharmaceuticals Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Salva Espinosa
Salva Espinosa Jul 13, 2021 10:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello all, What do you think or feel about this stock? Thanks!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email